Aquestive Therapeutics will resubmit the U.S. NDA for Anaphylm, its sublingual epinephrine film for severe allergic reactions, in the third quarter of 2026 after receiving a January 2026 Complete Response Letter focused on human factors and a single pharmacokinetics study linked to packaging and labeling changes. A Type A meeting with FDA is expected within 30 days. In parallel, the company plans 2026 regulatory applications in Canada and the EU, has extended its revenue-sharing agreement with RTW to June 30, 2027, and secured additional support through a warrant for 375,000 shares at $4.00 and a commitment by RTW-affiliated funds to purchase at least $5 million of stock over the next 90 days.
The strategic question is whether an oral, device-free rescue option can overcome FDA’s increasingly exacting human factors bar while convincing payers that convenience and portability translate into measurable outcomes in real-world emergencies. FDA did not question chemistry, manufacturing, or clinical comparability to auto-injectors, narrowing the U.S. path to an execution challenge: demonstrate that patients and caregivers can reliably open the pouch and correctly place the film under stress, and confirm PK with the updated presentation. That pivots the risk from biology to behavior—an area where Medical Affairs, human factors engineering, and patient training content will determine timelines and label strength.
Timing matters. The anaphylaxis market is expanding, but device-based standards are entrenched. If Anaphylm achieves approval on the revised timeline, it could open the first non-invasive oral route in a category long defined by auto-injectors, with implications for school systems, public venues, and travel settings where size, stigma, and needle fear drive under-carry and under-use. For patients and caregivers, a pocketable, water-free format could reduce barriers to carrying epinephrine; for HCPs, it introduces a new counseling paradigm that shifts from injection technique to rapid recognition and precise film placement. Payers will look for evidence that easier carriage and use lead to earlier administration, reduced ER utilization, and fewer biphasic events, making early RWE programs around time-to-dose and outcomes critical to access.
Aquestive’s hybrid model—proprietary assets plus a steady CDMO engine—remains central to funding the runway. Q4 2025 revenues rose to $13.0 million, driven by manufacture-and-supply revenue, with 47 million doses produced in the quarter across partnerships including Suboxone, Sympazan, Ondif, and Emylif. Year-end cash stood at $121.2 million, and the company guides to end 2026 with $70 million, excluding potential Anaphylm launch costs. 2026 outlook calls for $46–$50 million in revenue and a non-GAAP adjusted EBITDA loss of $30–$35 million, reflecting the planned human factors and PK work plus pre-commercial investment. The extended RTW agreement and equity support add flexibility but underline the importance of hitting regulatory milestones to avoid prolonged capital dependence.
Pipeline optionality provides a secondary vector. AQST-108, a topical epinephrine prodrug gel for dermatologic conditions including alopecia areata, completed dosing in a second Phase 1 study with data expected in Q2 2026. If local activity can be demonstrated without systemic exposure, the program could position against JAK inhibitors’ safety and cost profile, offering a differentiated entry into a sizable market while leveraging the same prodrug chemistry platform.
Across the industry, FDA’s scrutiny of human factors for at-home, time-critical therapies is reshaping development and launch design. Non-invasive rescue is moving from “nice to have” to a competitive necessity, but usability and label-anchored instructions will gate access and uptake. The next inflection comes quickly: can Aquestive generate compelling human factors and PK evidence on the compressed timeline, and will payers and health systems translate patient preference for an oral film into broad, front-line coverage once the device is removed from the equation?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
